U.S. markets closed

RegeneRx Biopharmaceuticals, Inc. (RGRX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2800+0.0050 (+1.82%)
At close: 3:42PM EDT

RegeneRx Biopharmaceuticals, Inc.

15245 Shady Grove Road
Suite 470
Rockville, MD 20850
United States
301 208 9191

Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Dr. Allan L. GoldsteinFounder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board90kN/A1938
Mr. J. J. FinkelsteinPres, CEO & Director83.38kN/A1952
Dr. Nabila A. Turjman Ph.D.Exec. Director of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Corporate Governance

RegeneRx Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.